Souhaitez-vous accéder aux communiqués récents ?

Significantly Expands Company’s R&D Capabilities to Advance Industry’s Largest Portfolio of Rare Disease Gene Therapy Programs State of the Art 75,000 Sq. Ft. Research Facility Across From...

2019 Galafold Revenue Nearly Doubled to $182.2M On Track to Achieve 2020 Revenue Guidance of $250M-$260M Focused on Pompe Phase 3 PROPEL Study, Manufacturing to Support 2021 BLA and MAA, and...

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen &...

CRANBURY, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at...

CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel...

2020 Galafold Revenue Guidance of $250M-$260M  Focused on Pompe Phase 3 PROPEL study and manufacturing to support 2021 BLA and MAA Continued Progress Across Industry Leading Rare Disease Gene...

Galafold Revenue of $181 Million for Full-Year 2019 and $54 Million in Q4 Reflects Continued Strong Adoption & Patient Adherence in All Key Global Regions Galafold Marketing Authorizations...

123 Patients Enrolled in Phase 3 PROPEL Study – Enrollment Completed in 4Q2019 Company Plans to Apply for and Initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020 with Addition...

           3Q19 Galafold® (migalastat) Revenue of $48.8M  and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M ...

CRANBURY, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019...